Replies to post #155743 on Biotech Values

[NP1986]

That's not bad, considering that approval for listing on public formularies in the major EU countries is probably still pending.

[DewDiligence]

What's INCY's royalty rate on NVS' sales of Jakavi?

[DewDiligence]

NVS/INCY—NICE rejects UK reimbursement for Jakavi:

http://www.reuters.com/article/2013/02/13/us-novartis-britain-jakavi-idUSBRE91C00Y20130213

The drug costs 3,600 pounds ($5,600) for a 60-tablet pack, corresponding to an annual cost of approximately 43,200 pounds ($67,200) per patient.

This is a preliminary decision; a final decision by NICE will be made in June.